Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF/EVG Vaginal Insert for HIV and HSV Prevention
NCT06087913Phase 1Completed
- Sponsor
- Eastern Virginia Medical School
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) and herpes simplex virus infection comparing TAF/EVG Insert with Placebo Insert (2 arms). Primary endpoint: Number and Severity of Adverse Events at 3 months. Started Nov 2023; status: completed.
02
Drugs
tenofovir alafenamideelvitegravir
03
Conditions
human immunodeficiency virus infection (HIV)herpes simplex virus infection
Beyond the preview
Go deeper on NCT06087913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087913.